XBKK
SKR
Market cap469mUSD
Nov 12, Last price
7.70THB
Name
Sikarin PCL
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sikarin Public Company Limited, along with its subsidiaries, functions as a healthcare provider managing hospitals throughout Thailand. The company delivers a comprehensive range of medical services and facilities, encompassing specialized care units for diabetes, endocrine disorders, general medicine, orthopedics, emergency and trauma, various surgical procedures, pediatric care, dentistry, aesthetic treatments, women's health, and fertility. Furthermore, it houses dedicated centers for gastroenterology, neurology, stroke, EENT (Ear, Nose, and Throat), and an international medical center. Diagnostic and therapeutic capabilities are robust, featuring a full laboratory department, diagnostic radiology, CT scan and MRI units, multiple operating rooms, a hemodialysis unit, a physical therapy department staffed with rehabilitation specialists, and a catheter laboratory. Patient accommodation includes intensive care units (ICUs), a coronary care unit (CCU), delivery rooms, nurseries, and a variety of inpatient wards such as general, international, obstetrics and gynecology, after heart and thoracic surgery, medical, and pediatric wards. Beyond its core healthcare operations, Sikarin also oversees the management of rental properties and is involved in the sale of food and beverages. The company's hospital portfolio includes Sikarin Hospital in Bangkok, equipped with 355 beds; Rattarin Hospital in Muang, offering 100 beds; and Sikarin Hat-Yai Hospital in Hat Yai, providing 350 beds. Established in 1979, Sikarin Public Company Limited is headquartered in Bangkok, Thailand.
Valuation
Title THB in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||